ejpmr, 2022,9(4), 257-264

SJIF Impact Factor 6.222

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Research Article

ISSN 2394-3211

EJPMR

DEVELOPMENT AND EVALUATION OF LOADED MICROSPHER OF MESALAZINE FOR COLON DRUG DELIVERY SYSTEM

Dhiraj Kumar*[1], Vandana Singh[1] and Dr. Shamim Ahmad[1]

Translam Institute of Pharmaceutical Education and Research Meerut, India.

***Corresponding Author: Dhiraj Kumar**

Translam Institute of Pharmaceutical Education and Research Meerut, India.

Article Received on 28/01/2022 **Article Revised on 17/02/2022** **Article Accepted on 09/03/2022**

ABSTRACT

The current concern is the fabrication and testing of gum microspheres that occur naturally in terms of performance, decay, readiness, cost-effectiveness and mesalazine. Mesalazine is used in the treatment of inflammatory disease. The microsphere mesalazine solution is prepared by the evaporation process using jantan gum and guar gum. Compliance studies in the range of 200 to 400 cm-1 using FTIR showed no significant changes in mesalazine signaling properties and content in all formulations, indicating mesalazine compatibility with auxiliaries. Adjusted microspheres were analyzed for particle size, surface appearance, % yield, efficiency drug efficiency, in vitro extra drug extraction studies, in-vitro drug kinetics and stabilization studies. Thus the microsphere is a bright yellow color and flows freely. Micrometric research of the prepared structure is available within specified limits and shows good mobility characteristics. Scanning electron microscopy (SEM) studies have demonstrated spherical shapes with diameters ranging from 100µm to 200µm. As the concentration of Shantan gum increases, the release of the drug inside the vitreous decreases. Experimental kinetics studies have shown that the prepared microspheres are kept in zero order and are controlled by the distribution of extra drug extraction from the microspheres and that the microspheres are stable. In conclusion, Microsphere provides an effective and efficient method of producing a controlled release of mesalazine with natural Shantan gum as a dose-regulating agent and to increase the dose frequency reduction.

KEYWORDS: Mesalazine; Xanthan gum; guar gum; microspheres; Solvent evaporation.

INTRODUCTION

Colon Targeted Drug Delivery Systems (CTDDS)

For the past 70 years it has had a detailed understanding of body function, structure, cell biology, membranes, cells, cellular organs, and gut processes related to gut processes in the intestinal tract Indigenous Intestinal Disorders Treatment (CTDDS) delivery drug delivery programs are on the rise. Drug delivery targeted at the colon is essential for the local treatment of various intestinal diseases such as ulcerative colitis, Crohn's disease, amoebiasis, colon cancer and local colon pathologies, as well as systemic delivery of protein and peptide the drug. 2 Migratory forms that bring the drug to the colon instead of the high have a number of advantages. The administration of the drug in the colon is important in the treatment of diseases of the colon, which can be achieved with a high local concentration while reducing side effects.

Need of colon targeted drug delivery

- Targeted drug delivery in the colon ensures direct treatment, low dosage and fewer side effects in the diseased area.
- On-site or targeted drug delivery systems allow drug administration of peptide and protein drugs, direct migration may also be used to facilitate colon drug delivery.
- The colon is a site that can reach local or scheduled drug delivery, local treatment for inflammatory disease, e.g. ulcerative colitis or Crohn's disease. Such inflammatory conditions are usually treated with glucocorticoids and sulfasalazine (REF).
- Many other serious diseases of the colon, e.g. for colorectal cancer, you can treat it with great success if the drug is taken at the colon.
- The structure of the colon delivery is also favorable for the distribution of polar and / or drug-induced chemical and enzymatic losses in the upper GI tract, which is largely influenced by hepatic metabolism, especially therapeutic proteins and peptides.

MATERIAL AND METHODS

PRE-FORMULATION STUDIES

Designs to produce useful designer information on creating stable and available scale forms, which can be produced on a bulky scale. A better considerate of the physicochemical possessions can eventually give a reason for the structure or maintenance the essential for

molecular alteration or simply ensure that there are no important fences to chemical development. The objectives of the database are therefore:

a. To inaugurate the essential physicochemical properties of a novel medicine material.
b. Determining its kinetration level outline.
c. Inaugurate its compatibility through dissimilar adversaries.

Therefore, preconstruction readings on the acquired medication sample included corporeal exams and compliance studie.

IR Spectroscopy

FRIR spectroscopy is performed to look for interactions b/w drugs and extensions. IR spectroscopy is performed by thermo-Nicolet FTIR, the range is noted in a expanse of 200 to 400 cm^{-1}. by smearing compression of 5 tons for 5 min in newspapers. Interactions between drugs were revealed from an IR-spectral study looking at any changes in drug tops at the physical level of drug users.

Solubility Analysis

Pre-naming solvent examination is performed to choice the appropriate flush system to melt the medicine and the several materials used in the manufacture of microspheres.

Melting Point Determination

Determination of the melting-point of a sample of the found drugs was performed as the 1st indicator of clarity of the drug. The occurrence of a minor quantity of impurities can be noticed by reduction and magnification at the point of melting point. Mesalazine melting point was dignified by Thiele's tube tools.

Determination of λmax

Mesalazine was dispersed at 0.1NHCL with a phosphate buffer pH6.8, auxiliary purified and scanned for high absorption on a UV double beam spectrophotometer (shimadzu 1800) at a distance of 200 to 400 nm, 0.1 NHCL and phosphate buffer pH6.8 as empty.

Standard Calibration Curve of Mesalazine

Table 1: Formulation of Microspheres.

Formulation	Drug (mg)	Xanthan gur (mg)	Guar gum (mg)	Liquid paraffin (ml)	Span 80 (v/v)
F_1	100	10	-	150	0.6
F_2	100	15	-	150	0.6
F_3	100	20	-	150	0.6
F_4	100	25	-	150	0.6
F_5	100	-	15	150	0.6
F_6	100	-	20	150	0.6
F_7	100	-	25	150	0.6
F_8	100	-	30	150	0.6
F_9	100	-	35	150	0.6

Formulation of Microspheres

Microspheres are formulated by various dosages of the drug natural chewing gum (1:1.16, 1: 1.20, 1:1.26). The gums are allowed to soak in 20ml of water for three hours. The estimated weight (100 mg) was dissolved in 10ml of methylene-chloride and added to the aqueous sol^n of the gums. The beyond dispersion of the drug is infused with 0.5 ml of concentrated sulfuric acid to provide a clear viscous solution. The resulting solution was placed in an oily phase by pouring 200 ml of paraffin liquid containing 0.5% w / w span 80 as an emulsifying agent. The equipment was stirred at 1800 rpm for 210 minutes using a stirrer and heated by a hot plate at 500C. 1.2% / v dichloromethane was added as an encapsulating agent and 0.15% w / v of gluteraldehyde as a linking, regeneration and heating agent was maintained for 2.5 hours until the aqueous phase was completely removed by evaporation. The reduced oil and the collected microspheres are washed with water to remove the residue by touching and three times with 100 ml of n-hexane aliquots, filtered through whatman paper paper, dried in the oven at 800C for 2 hours indirect, hard, free flowing microspheres and kept on desiccators at room temperature.

EVALUATION OF Mesalazine MICROSPHERES

Micromeritic Studies

The ready microspheres to characterize through their micrometrics properties like as microsphere size, tapped-density, Carr's-compressibility index, Hausner's-ratio and angle of repose.

The angle of Repose

It is measured through funnel technique. Funnel is set on a flask stand at a specific peak . A chart wrapper is put under the funnel on a table. The crush is passing slowly across the funnel, until if form a pile. The blend powder is stop when the pile touches the tip of the funnel. Circumference of the pile of powder blend is drawn with the pancil without disturbing the pile. The radius of the pile 'r' is noted. the angle of repose was calculated using the following equation (table no. 2.7).

$$\tan \theta = h / r$$

Hence, $\theta = \tan^{-1} h/r$

Where, θ = angle of repose

h = height of the cone

r = radius of the cone base
The under the angle of repose, finer the move effects, when granules are placed in the hopper & allowed to slide down into the die for compression. It forms tablets. The angle of repose may be deliberate by determine the length (h) of the tablets and radius of the base (r) with the ruler. The angle of repose shows in between 30-40°C, which is considered as a passable flow of granules.

Bulk Density
Mass density is the ratio of total mass of powder to the bulk volume of powder. It is evaluated via taken the weigh amount of blend crush beginning every preparation in a fifty ml test tube moreover the original quantity of the residue to calculate was written. The mass density of crush be obtained through the formula,(table no. 3.7)

$$P_b = M/ V_b$$

Where.
P_b = mass-density
m= Total mass of residue
v_b = mass volumeof residue

Tapped density
It is defined as whole mass of the dust is separated through tapped quantity of the dust. It is calculated by taken the grind in measuring cylinder and tapping the dust with seven thundered fifty count. The tapped level be marked. The difference b/w tow tapping less than two present, if the difference > 2%, the tapping continued with 1250 times and the tapped volume is marked. The drumming regular when the difference b/w two tapping successive volume is less than 2%. It is calculate by the following formula, (table no. 3.7).

$$p_t = m/ v_t$$

P_t = Tapped-density
M = total mass of residue
V_t = tapped capacity of powder

Compressibility Index
The compressibility of the grind was calculated through Carr's Compressibility Index.

Carr's compressibility index (%) = [(TBD-LBD) X 100]/TBD

Or it can be expressed as Carr's Index relates the poured density of the material to the tapped density and was calculated by using the following relationship:

$$\text{Compressibility Index} = \frac{\text{Tapped density – bulk density}}{\text{Density Tapped}} \times 100$$

Carr's Index values for pure drug, crosspovidone, and granule be evaluated with measuring the primary volume (Vp) and finishing volume (Vt) of celebrated mass (W) of substance after introduce to hundred pushing in a graduated test tube. Since this dimensions, the poured density (W/Vp) and the tapped density (W/Vt) assessment were considered and were substitute within the above equation to evaluate Carr's Index (Table 3.7).

Hausner'sratio: this is the ratio of tapped density to bulk density. It is calculated by the following formula, (table no. 3.7) Hausner's ratio = tapped density / bulk density.

Particle Size Determination: The particle size of the microspheres was measured by visual microscopy technique. About 100microspheres are calculated from the particle size by a observable optical microscope.

Morphological Study using SEM: Morphological research was performed by Perusing Electron Microscope (SEM). Microspheres scanned and tested beneath the Electrons Microscope HITACHI SU-1500, Japan associated to a acceptable coat, JEOL JFC 1100 E Ion sputter. The sample was shipped to the owner of a copper sample and a carbon-coated suit monitored by Gold.

Drug Loading and Drug Entrapment Microspheres equal to 50mg of the remedy were booked for testing. The quantity of drugs seized was assessed through devastating microspheres and releasing aliquots of 0.1NHCl (pH - 1.2) over and over again. The extraction was shifted to a 100ml volumetric bottle; the capacity was generated by 0.1NHCl (pH-1.2). The sol^n was clean; the absorption was determined afterward positive spectro-photometrically purification (UV-1700, Shimadzu, Japan) at 212nm compared with a suitable vacuum. The number of drugs burdened and trapped in microspheres is considered through the subsequent formulas:

$$\% \text{ Drug loading} = \frac{\text{Weight of the drug loaded in the microspheres(DC)}}{\text{Total weight of the microspheres}} \times 100$$

$$\% \text{ Drug entrapment} = \frac{\text{Amount of drug actually prsent(DC)}}{\text{Theoretical drug loaded expected}} \times 100$$

Percentage yield

$$\% \text{ yield calculated by following equation} = \frac{\text{Practical yield}}{\text{Theoritical yield}} \times 100$$

In vitro drug release Study[24]
Prepared microspheres are incorporated into the in vitro extract in sequence from three different sources of suitable dispersion. USP classification tools used. The first 2-hour reduction method was 900ml of 0.1 NHCl (pH 1.2) and continued to phosphate buffer pH6.8 for the succeeding seven hours. The temperature of the reduction was upheld at 37±0.5 °C and the bag was rotated 50 minutes. The 5ml aliquot was withdrawn at regular intermissions and was substituted by an equivalent volume of the new dispersion area to uphold immersion circumstances. Samples were examined at 272nm, with a percentage exposure to the remedy by a UV Visible-double beam spectro-photometer. The release studies was conducted three times.

Dissolution studies
Apparatus: LABINDIA USP Type II Dissolution media: 0.1 N HCl (pH-1.2)Speed: 100 rpm

Volume of medium: 900 mL

Aliquots taken at each time interval: 5 mL Temperature: 37±0.5°C
Wavelength: 272 nm

4.6. Release Kinetics[53]

Matrix methods are described to monitor Pappas' emission rate and drug distribution method. To analyze the extraction method and the release of the kinetics measurement of the equation form, the statistics gotten were placed in Zero order, first order, Higuchi model, Peppas and Hixson Crowell. In this case by comparing the r values obtained, the most suitable model was selected.

RESULT AND DISCUSSION

PRE-FORMULATION STUDIES

COMPATIBILITY STUDY

IR Spectroscopy



Figure 1: IR-Spectrum of pure drug Mesalazine.



Figure 2: Standard Calibration Curve of Mesalazine in 0.1N HCL.

Micrometric Assets

Table 2: Micrometric assets of Mesalazine microspheres.

Preparation code	Bulkdensity (g/cm^3)	Tappeddensity (g/cm^3)	Compressible index(%)	Hausner'sratio	Angleof repose
F_1	0.4427±0.006	0.6232±0.007	14.67±1.23	1.168±0.04	27.95±0.25
F_2	0.4987±0.009	06524±0.005	15.32±1.34	1.176±0.07	26.74±0.26
F_3	0.5335±0.016	0.7245±0.009	17.33±1.36	1.203±0.021	33.95±0.19
F_4	0.4925±0.009	0.6445±0.006	12.46±1.36	1.143±0.020	34.89±0.16
F_5	0.5419±0.014	0.6282±0.002	13.73±1.06	1.150±0.03	29.69±0.26
F_6	0.6277±0.012	08163±0.014	14.65±1.04	1.167±0.08	28.09±0.18
F_7	0.4686±0.015	0.6364±0.009	13.47±1.12	1.153±0.04	34.36±0.63
F_8	0.4864±0.012	0.6856±0.013	16.42±1.06	1.338±0.025	35.56±1.10
F_9	0.5438±0.016	0.7423±0.015	16.46±0.86	1.193±0.36	38.13±1.56



Figure 3: Comparison of Avg. Particle Size of the Prepared MicrospheresScanning Electron Microscopy.

Table 3: Drug Loading and Drug Entrapment of Mesalazine Microspheres.

Formulation Code	Actual Drug Content (mg)	Theoretical Drug Content(mg)	Total Weightof Microspheres (mg)	% DrugLoading	%Drug Entrapment
F1	19.28	25	50	38.57	78.12
F2	14.76	16.69	50	27.6	82.48
F3	11.33	12.5	50	22.62	90.40
F4	19.51	25	50	21.06	92.12
F5	12.94	16.69	50	37.88	73.62
F6	11.45	12.5	50	32.86	78.44
F7	19.74	25	50	29.44	84.88
F8	14.16	16.67	50	28.32	86.94
F9	11.57	12.7	50	23.12	92.48



Figure 4: Comparison of % Drug Loading of the Prepared Microspheres.

MicrospheresPercentage yield

Table 4: Practical Yield of Mesalazine Microspheres.

FormulationCode	TheoreticalWt (mg)	Practical Yield (mg)	%Yield
F1	1000	753	79.22
F2	1500	1096	75.85
F3	2000	1295	67.67
F4	1000	763	61.55
F5	1500	1098	81.20
F6	2000	1289	71.4
F7	1000	748	70.7
F8	1500	1088	59.69
F9	2000	1310	55.50



Figure 5: Comparison of % Yield of the Prepared Microspheres.

***In-vitro* drug release studies**

Table 5: *In–vitro* drug release for Mesalazine Microspheres in 0.1N HCL (pH 1.2)and (pH 6.8) phosphate buffer.

Time (hrs)	CUMULATIVE % DRUG RELEASE OF FORMULATION								
	F1	F2	F3	F4	F5	F6	F7	F8	F9
0	0	0	0	0	0	0	0	0	0
1	17.215	16.557	14.472	13.959	17.215	16.959	16.553	14.141	13.093
2	28.410	25.765	24.433	22.557	35.765	26.557	20.535	18.370	17.085
3	34.714	32.406	31.723	29.146	42.406	39.146	25.844	23.465	22.431
4	47.375	38.389	37.073	31.811	48.389	38.811	31.817	29.634	27.563
5	52.038	43.050	41.369	34.477	53.050	44.477	32.497	31.050	30.774
6	59.000	54.998	49.069	49.063	64.998	51.063	39.136	39.360	37.124
7	63.306	62.318	53.716	45.712	72.318	56.712	54.469	48.156	44.744
8	69.320	68.331	65.697	64.350	76.331	63.350	61.803	59.691	49.424
9	75.633	72.994	69.020	67.669	79.994	71.669	68.447	66.313	65.768
10	81.723	79.038	76.389	71.558	82.146	80.574	74.474	69.093	63.568



Figure 6: Comparative *In-vitro* Dissolution Profile of Mesalazine Microspheres.

Release Kinetics

Table 6: Model Fitting Release Profile of Mesalazine Microspheres.

Formulationcode	Mathematical Models (Kinetics)						Best FitModel
	Korsmeyer–Peppas		Higuchi	Hixson–Crowell	First Order	Zero order	
	R^2	N	R^2	R^2	R^2	R^2	
F1	0.9406	0.4596	0.9634	0.9668	0.8893	0.9894s	Zero order
F2	0.9353	0.4480	0.9688	0.9636	0.8977	0.9834	Zero order
F3	0.9238	0.4409	0.9499	0.9308	0.8678	0.9553	Zero order
F4	0.943	0.4374	0.9748	0.9731	0.9084	0.9914	Zero order
F5	0.9466	0.4574	0.9749	0.9686	0.9103	0.9868	Zero order
F6	0.9349	0.4232	0.9618	0.9422	0.8874	0.9636	Zero order
F7	0.968	0.4460	0.9908	0.9899	0.9304	0.9963	Zero order
F8	0.972	0.4192	0.9885	0.9868	0.9479	0.9942	Zero order
F9	0.9676	0.4358	0.9855	0.9809	0.9471	0.9896	Zero order

Korsmeyer-Peppas model for prepared Microspheres



Figure 7: Korsmeyer-Peppas release Kinetics for prepared microspheres.

Stability study

Table 7: Stability Studies for Formulations Stored at 40°C/75% RH.

Tested after days	% Drug entrapment		% CDR	
	F1	F5	F1	F5
15	78.13	73.29	81.724	82.176
30	77.38	73.28	80.234	82.148
45	77.42	72.24	81.172	81.765
60	78.27	72.32	81.69	82.251

CONCLUSION

Current research reports a novel attempt to create microspheres of Mesalazine using natural gums such as xanthan gum and guar gum as a carrier for better treatment of inflammatory bowel disease. Microspheres Mesalazine is prepared by solvent evaporation. Various experimental frameworks were tested, with the aim of determining the controlled release of Mesalazine.

Details regarding structural adjustments and inspections are discussed in the preceding chapters. In the study the following conclusions can be drawn,

- FTIR studies have shown that the drug is compatible with all combined substances.
- Natural gums such as xanthan gum and guar gum can be used to build microspheres.
- Micromeritic studies revealed that the particle size used for the prepared microspheres was between 279 ± 7.15 to 993 ± 10.85 µm.
- SEM analysis of microspheres revealed that guar gum containing microspheres was smoother, more rounded and compacted than the microspheres of xanthan gum, which was more aggressive, aggressive, more aggressive.
- A good percentage of drug capture and active yields were obtained by all polymers. As the number of polymers increases the number of drug loads decreases agai.
- The efficiency of the capture of% has been increased due to the increased viscosity of the solution.
- The percentage release of the drug increases significantly with increased polymer concentration.

- The total curve equal to the different types of mathematics was found to be in balance. The F1 to F9 formulations were better suited to the zero-order kinetic model and drug extraction in the formulation was a non-Fickian method of distribution.
- Selected microspheres of F1 and F5 were stable and corresponding to the selected temperature and humidity in storage for 60 days.
- From stability studies it has been found that there is no significant change in drug seizures, as well as signs of in vitro drug release in microspheres.
- Thus, artificial microspheres appear to be potential candidates as an oral drug delivery system that increases drug retention in GIT.

REFERENCES

1. Sanghi DK, Rakesh Tiwle. Medical Rational Of Colloidal Drug, Gene Delivery And It's Characterization Aspects. International Journal of Innovative Drug Discovery, 2016; 6(1): 8-17.
2. Jaideep Bhardwaj, Sayantan Mukhopadhyay, Dr. Lakshmayya. Colon Targeted Drug Delivery: A Review. International Journal of Pharmaceutical & Biological Archives, 2013; 4(4): 596–605.
3. Shinde VS, Shinkar DM, Saudagar RB. Review On-Colon Targated Drug Delivery System. International Journal of Universal Pharmacy and Bio Sciences, 2015; 4(6): 47-66.
4. Ratnaparkhi Mukesh P, Somvanshi Fattesingh U, Pawar Sham A, Chaudhari Shilpa P, Gupta Jyoti P, Budhavant Kalyani A. Colon Targeted Drug Delivery System. International Journal of Pharma Research & Review, 2013; 2(8): 33-42.
5. Asha Patel, Nilam Bhatt, Dr. Patel KR, Dr. Patel NM, Dr. Patel MR, Shree BM. Colon Targeted Drug Delivery System: A Review System. Journal Of Pharmaceutical Sciences And Bioscientific Research, 2011; 1(1): 37-49.
6. Asija rajesh, chaudhari bharat, asija sangeeta. Oral colon targeted drug delivery system:Areview On Current And Novel Perspectives. journal of pharmaceutical and scientific innovation, 2012; 1(5): 6-12.
7. Amritpal Singh, Ankush Sharma, Sukhbir Kaur. Micro Carrier As Colon Drug Delivery System: A Review. International Journal Of Research And Development In Pharmacy And Life Sciences, 2013; 3(6): 1211-1216.
8. Pradhi Srivastava, Sharad Visht. Application and advancement of microsphere as controlled. International Journal Of Pharmacy & Life Sciences, 2013; 4(4): 2583-2594.
9. Nisha Sharma, Neha Purwar, Prakash Chandra Gupta. Microspheres As Drug Carriers For Controlled Drug Delivery: A Review. International Journal Of Pharmaceutical Sciences And Research, 2015; 6(11): 4579-4587.